Literature DB >> 19525927

Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study.

Guo-Xia Tong1, Woojin M Yu, Nike T Beaubier, Erin M Weeden, Diane Hamele-Bena, Mahesh M Mansukhani, Kathleen M O'Toole.   

Abstract

Cell-lineage-specific transcription factors are a group of regulatory proteins expressed in embryonic, differentiated, or neoplastic cells of the same lineage and represent a valuable repertoire of tissue-specific markers for the diagnosis of human tumors. Together with PAX2, PAX8 is a nephric-lineage transcription factor and is required for the establishment of renal-lineage cells and the formation of the kidney. In contrast to PAX2, little is known about the expression of PAX8 in adult kidney and renal tumors. In this study, we used immunohistochemistry to investigate the expression of PAX8 in adult human kidney and renal epithelial tumors. We report here that PAX8 was detected in renal epithelial cells in all segments of renal tubules from the proximal tubules to the renal papillae and in the parietal cells of Bowman's capsule in the adult kidney. PAX8 was also present in 98% of clear cell renal cell carcinomas (RCCs), 90% of papillary RCCs, and 95% of oncocytomas, similar to PAX2. In addition, PAX8 was found in 82% of chromophobe RCCs, 71% of sarcomatoid components of RCCs, and 100% (2/2) of renal medullary carcinomas. Overall, PAX8 was detected in 85% of metastatic renal tumors. Interestingly, expression of PAX8 was noted in some urothelial cells in the renal pelvis and ureters and approximately 23% of urothelial carcinomas of the renal pelvis, but not in the urothelium or urothelial carcinomas of the urinary bladder; this probably underlines the different embryonic origins of urothelial cells in the upper and lower urinary tracts. As shown in this study, PAX8 is widely expressed in normal and neoplastic renal tissues. PAX8 may be a useful additional marker for renal epithelial tumors; however, its specificity and sensitivity await further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525927     DOI: 10.1038/modpathol.2009.88

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  47 in total

Review 1.  Cervical lymph node metastases from remote primary tumor sites.

Authors:  Fernando López; Juan P Rodrigo; Carl E Silver; Missak Haigentz; Justin A Bishop; Primož Strojan; Dana M Hartl; Patrick J Bradley; William M Mendenhall; Carlos Suárez; Robert P Takes; Marc Hamoir; K Thomas Robbins; Ashok R Shaha; Jochen A Werner; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-12-29       Impact factor: 3.147

2.  Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases.

Authors:  Ankur R Sangoi; Mika Fujiwara; Robert B West; Kelli D Montgomery; Joseph V Bonventre; John P Higgins; Robert V Rouse; Neriman Gokden; Jesse K McKenney
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

3.  The direction and role of phenotypic transition between podocytes and parietal epithelial cells in focal segmental glomerulosclerosis.

Authors:  Kazuo Sakamoto; Toshiharu Ueno; Namiko Kobayashi; Satoshi Hara; Yasutoshi Takashima; Ira Pastan; Taiji Matsusaka; Michio Nagata
Journal:  Am J Physiol Renal Physiol       Date:  2013-10-23

4.  Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

Authors:  Chisato Ohe; Steven C Smith; Deepika Sirohi; Mukul Divatia; Mariza de Peralta-Venturina; Gladell P Paner; Abbas Agaimy; Mitual B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Maurizio Colecchia; Eva Compérat; Isabela Werneck da Cunha; Jonathan I Epstein; Anthony J Gill; Ondřej Hes; Michelle S Hirsch; Wolfram Jochum; Lakshmi P Kunju; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Gabriella Nesi; Adeboye O Osunkoya; Maria M Picken; Priya Rao; Victor E Reuter; Paulo Guilherme de Oliveira Salles; Luciana Schultz; Satish K Tickoo; Scott A Tomlins; Kiril Trpkov; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

5.  Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.

Authors:  Yi-Feng Gu; Shannon Cohn; Alana Christie; Tiffani McKenzie; Nicholas Wolff; Quyen N Do; Ananth J Madhuranthakam; Ivan Pedrosa; Tao Wang; Anwesha Dey; Meinrad Busslinger; Xian-Jin Xie; Robert E Hammer; Renée M McKay; Payal Kapur; James Brugarolas
Journal:  Cancer Discov       Date:  2017-05-04       Impact factor: 39.397

6.  PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?

Authors:  Meaghan L Barr; Lucia B Jilaveanu; Robert L Camp; Adebowale J Adeniran; Harriet M Kluger; Brian Shuch
Journal:  J Clin Pathol       Date:  2014-10-14       Impact factor: 3.411

Review 7.  Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms.

Authors:  Georgios Kyriakopoulos; Vasiliki Mavroeidi; Eleftherios Chatzellis; Gregory A Kaltsas; Krystallenia I Alexandraki
Journal:  Ann Transl Med       Date:  2018-06

8.  Long non-coding RNA PAX8-AS1 polymorphisms increase the risk of childhood acute lymphoblastic leukemia.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Simin Sadeghi-Bojd; Mohsen Taheri
Journal:  Biomed Rep       Date:  2017-12-13

9.  Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms.

Authors:  Randall T Butler; Megan A Alderman; Lester D R Thompson; Jonathan B McHugh
Journal:  Head Neck Pathol       Date:  2014-04-26

10.  De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease.

Authors:  Takamoto Ohse; Michael R Vaughan; Jeffrey B Kopp; Ronald D Krofft; Caroline B Marshall; Alice M Chang; Kelly L Hudkins; Charles E Alpers; Jeffrey W Pippin; Stuart J Shankland
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.